Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18622063 | 1.00 | TYR (0.46) | TYRTHRBLMNACA12CA9 | |
| SCHEMBL26385620 | 1.00 | TYR (0.46) | TYRTHRBLMNACA12CA9 | |
| SCHEMBL11034505 | 0.95 | TYR (0.42) | TYRTHRBLMNACA12CA9 | |
| SCHEMBL6930937 | 0.95 | TYR (0.42) | TYRTHRBLMNACA12CA9 | |
| SCHEMBL26443544 | 0.83 | TYR (0.35) | TYR | |
| SCHEMBL25976247 | 0.83 | TYR (0.35) | TYR | |
| SCHEMBL11082587 | 0.82 | TYR (0.50) | TYRTHRBCA12CA9CA1 | |
| SCHEMBL11080316 | 0.79 | TYR (0.42) | TYRTHRBLMNACA12CA9 | |
| SCHEMBL6932467 | 0.78 | TYR (0.32) | TYR | |
| SCHEMBL23488810 | 0.78 | TYR (0.41) | TYRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017103790-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | TYR 325/4885THRB 4818/4885LMNA 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.